Jump to content
  • entries
  • comments
  • views

About this blog

This blog is an aggregation of credible lung cancer news and useful information to help anyone impacted by lung cancer.

Entries in this blog

Immunotherapy Drug Boosts Survival for Lung Cancer Patients

https://consumer.healthday.com/cancer-information-5/lung-cancer-news-100/immunotherapy-drug-boosts-survival-for-lung-cancer-patients-761655.html   THURSDAY, Oct. 1, 2020 (HealthDay News) -- A newly approved drug for the leading form of the number one cancer killer, lung cancer, does improve patient survival, a new study confirms. The immunotherapy drug Tecentriq (atezolizumab) was approved earlier this year by the U.S. Food and Drug Administration to treat patients with newly diag

Improved Therapeutic Efficacy of Topotecan Against A549 Lung Cancer Cells with Folate-targeted Topotecan Liposomes

https://pubmed.ncbi.nlm.nih.gov/32851958/ 8/20/2020, Online ahead of print. Abstract Background: Among all cancers, lung cancer has high mortality among patients in most of countries in the world. Targeting delivery of anticancer drugs can significantly reduce the side effects and dramatically improve the treating effect. Folate, which is one suitable ligand, can be modified to the surface of tumor-selective drug delivery systems. Because it can selectively bind to the folate rece

Lung Cancer Treatment Continues to Improve

https://www.oncnursingnews.com/web-exclusives/lung-cancer-treatment-continues-to-improve CAROLINE SEYMOUR Sunday, July 26, 2020   Histological subtyping of lung cancer is still clinically important, said Ignacio I. Wistuba, MD. However, additional parameters such as driver alterations, alternative methods for molecular testing, and immunotherapy-related biomarkers have strengthened the diagnostic and treatment paradigms in lung cancer. The diagnostic algorithm for lung can

University of Dundee Researchers destroy ‘undruggable’ cancer-causing K-Ras protein

By EH News Bureau On Jul 17, 2020 https://www.expresshealthcare.in/news/university-of-dundee-researchers-destroy-undruggable-cancer-causing-k-ras-protein/423434/ Researchers at Scotland-based University of Dundee have demonstrated a new method of destroying an ‘undruggable’ protein known to play a role in cancer, raising the possibility of a new therapeutic approach to the disease. Mutations of the K-Ras protein have long been known to cause many cancers, including lung, colorecta

Draft USPSTF guidance lowers recommended age to start lung cancer screening

https://www.healio.com/news/hematology-oncology/20200707/draft-uspstf-guidance-lowers-recommended-age-to-start-lung-cancer-screening July 07, 2020 Individuals with a smoking history should begin annual screening for lung cancer at age 50 years instead of age 55 years, according to a draft recommendation issued by the U.S. Preventive Services Task Force. The recommendation, an update of USPSTF guidance on lung cancer screening issued 7 years ago, also reduces smoking pack-year elig

Triathlete with Stage 4 lung cancer completes cross-country trek

https://communitynews.org/2020/06/25/lawrence-triathlete-with-stage-4-lung-cancer-completes-cross-country-trek/ By Nicole Viviano June 25, 2020 Biking across the United States is a memorable feat for anyone. One endurance athlete from Lawrenceville managed to complete the Southern Tier bike route while facing down an even greater obstacle: Stage 4 lung cancer. Isabella de la Houssaye, 56, has lived an active lifestyle, from mountain climbing to Ironman triathlons. Her love of

Adjuvant Osimertinib On Way to Becoming New Standard in EGFR-Mutant NSCLC

https://www.onclive.com/view/adjuvant-osimertinib-on-way-to-becoming-new-standard-in-egfr-mutant-nsclc Roy S. Herbst MD, PhD, discusses the ADAURA trial and the impressive data seen with adjuvant osimertinib and highlights ongoing research efforts being made with the agent in lung cancer. JUNE 16, 2020 The significant and clinically meaningful improvement in disease-free survival (DFS) demonstrated with adjuvant osimertinib (Tagrisso) in patients with EGFR-mutated, stage I, II, an

Revolution Medicines Doses First Patient in Study of SHP2 Inhibitor With Amgen's KRAS Inhibitor

Original article post on Jun 09, 2020 on Precision Oncology News NEW YORK – Revolution Medicines announced today that it has dosed the first patient in a Phase Ib clinical trial evaluating its investigational SHP2 inhibitor, RMC-4630, in combination with Amgen's KRAS G12C inhibitor AMG510. The open-label, dose escalation and expansion study, sponsored and conducted by Amgen, is evaluating the combination in patients with advanced solid tumors characterized by KRAS G12C mutations. Revol

AI can categorize lung nodules' cancer risk, study suggests

AI can categorize lung nodules' cancer risk, study suggests Katie Adams A new artificial intelligence algorithm can accurately assess the risk of cancer associated with indeterminate pulmonary nodules in patients' lungs, according to a study published in American Journal of Respiratory and Critical Care Medicine. Traditionally, physicians use CT scans to assess lung nodules, which can lead to earlier cancer diagnoses. However, this approach can also lead to overtreatment if nodule

Melanoma Immunotherapy Offers Hope for Lung Cancer

By Kim Polacek, APR, CPRC - April 27, 2020   An immunotherapy that has demonstrated durable responses in patients with melanoma is now showing promise for those with non-small cell lung cancer. Tumor infiltrating lymphocyte therapy, or “TIL,” uses a patient’s own live immune cells to fight cancer. Surgeons remove a patient’s tumor and, in the lab, dissect and culture the T cells inside. These cells, which were able to detect and invade the tumor, are then multiplied by the billions — a

A Simpler Way to Sample: Liquid Biopsies in Lung Cancer

Liquid biopsies are easier on patients, yield faster results and cost less than tissue biopsies, but these blood draws don’t yet replace traditional tests. https://www.curetoday.com/publications/cure/2020/lung-1-2020/a-simpler-way-to-sample-liquid-biopsies-in-lung-cancer BY MEERI KIM, PH.D. PUBLISHED APRIL 20, 2020 During winter 2013, Larry Gershon had a bad cold that he couldn’t shake. The then 65-year-old print broker took cold medicine and steroids to fight off the symptom

How the New Coronavirus May Affect Lung Cancer Treatment

https://www.cancerhealth.com/article/new-coronavirus-may-affect-lung-cancer-treatment-1 Given recent findings that cancer patients may be at higher risk of contracting the new coronavirus if they visit medical centers, the Lung Cancer Foundation of America (LCFA) has issued a work-in-progress advisory for lung cancer patients and their doctors on how to navigate cancer treatment during the pandemic. The guidance is specific to people with non-small-cell lung cancer (NSCLC), which accou

Surviving Coronavirus as a Lung Cancer Survivor

With everyone on edge during the coronavirus pandemic, I wanted to share this story of a lung cancer survivor who has fully recovered from the virus.     Man who lost lung battling cancer survives coronavirus decade later https://bit.ly/39LM8Br BEAVER COUNTY, Pa. — A Pennsylvania man who lost a lung to cancer about a decade ago has survived another health battle -- this time, with the coronavirus. It started as what he assumed was just a cold, but when Richard Botti, 61,
  • Create New...